TrialThe Lancet. Infectious diseases2017

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.

James S McCarthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.